Article

Rucaparib May Potentially Benefit Patients with Advanced Pancreatic Cancer

Author(s):

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer

may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2

mutation, according to findings from a phase 2 trial.

With a poor prognosis and limited treatment options, pancreatic cancer is projected to become the second leading cause of cancer death by 2020. Approximately 9% of pancreatic cancers have a BRCA1 or BRCA2

mutation. As studies of BRCA1/2

mutations in breast and ovarian cancer have shown clinical benefit with PARP inhibitors, researchers sought to determine the clinical benefit in patients with pancreatic cancer.

The global, phase 2 study enrolled 19 patients aged 18 and older with locally advanced or metastatic pancreatic cancer with a known BRCA1/2

mutation between April 2014 and April 2016. Patients could have received up to 2 prior lines of chemotherapy but could not have received prior therapy with a PARP inhibitor.

Click to continue reading on The American Journal of Managed Care.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com